amrinone has been researched along with Prostatic Hyperplasia in 1 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurokawa, Y | 1 |
| Kojima, K | 1 |
| Kanayama, H | 1 |
| Kagawa, S | 1 |
| Minami, K | 1 |
| Nakaya, Y | 1 |
1 other study available for amrinone and Prostatic Hyperplasia
| Article | Year |
|---|---|
Activation of the Ca2+-activated K+ channel via protein kinase A-dependent phosphorylation in human prostatic smooth muscle cells.
Topics: Adenylyl Cyclases; Amrinone; Calcium; Cells, Cultured; Colforsin; Cyclic AMP; Cyclic AMP-Dependent P | 1998 |